A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
A phase 1/2 trial of Pembrolizumab in gastric & gastro-oesophageal junction cancer, run by Servier Bio-Innovation LLC, active and no longer recruiting.
Overview
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. is a phase 1/2 interventional study registered as NCT06116136 by Servier Bio-Innovation LLC, with 48 participants enrolled, started 2024-08-31 and due to reach its primary completion in 2027-08. Interventions recorded: S095029 and pembrolizumab 200 mg (KEYTRUDA ®).
Similar pages
not linked directly; found by shared links- TrialA Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
Shares Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
Shares Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialPhase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialBC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialSafety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
Shares Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Shares Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialKEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Shares Merck & Co. (MSD), Pembrolizumab and the tag pipeline.